Sheila Barbarino
Ophthalmology · Austin, TXNPI 1659578698
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Merz North America, Inc. accounts for 71.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $71,352 and has fallen 76.8% since, to $16,536 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $482.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$165K
- Galderma Laboratories, L.p.$62K
- Galderma Research & Development, LLC$2K
- AbbVie$920
- Revance Therapeutics, Inc.$617
- Musculoskeletal Transplant Foundation Inc.$399
- plus $381 from 4 others
Across 8 payments — averaging $2918.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$23K
What the payments were for
- Consulting fees$105,39045%
- Speaking & faculty fees$59,75026%
- Travel & lodging$42,72818%
- Food & beverage$22,58010%
- Education$1,2031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 338 | $164,838 |
| Galderma Laboratories, L.p. | 106 | $62,266 |
| Galderma Research & Development, LLC | 1 | $2,231 |
| AbbVie | 10 | $920 |
| Revance Therapeutics, Inc. | 10 | $617 |
| Musculoskeletal Transplant Foundation Inc. | 8 | $399 |
| Endo Pharmaceuticals Inc. | 4 | $228 |
| Motiva USA, LLC | 1 | $75 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $53 |
| VYNE Pharmaceuticals Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$231,651 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$240K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Robert WongAustin$113K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
- Michael SingerSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.